Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Blackmon

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialKatherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2012
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive valuePatrick G Gavin, Linda H Colangelo, Debora Fumagalli, et al.
Journal of the National Cancer Institute|November 23, 2013
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31Katherine L Pogue-Geile, Chungyeul Kim, Jong-Hyeon Jeong, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialKatherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2012
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive valuePatrick G Gavin, Linda H Colangelo, Debora Fumagalli, et al.
Journal of the National Cancer Institute|November 23, 2013
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31Katherine L Pogue-Geile, Chungyeul Kim, Jong-Hyeon Jeong, et al.
Pageof 5